Phase II study of modified FOLFIRINOX as neoadjuvant chemotherapy for borderline resectable pancreatic cancer and locally advanced unresectable pancreatic cancer - Phase II study of modified FOLFIRINOX as neoadjuvant chemotherapy for borderline resectable pancreatic cancer and locally advanced unresectable pancreatic cancer

Tokyo Medical University Department of Gastrointestinal and Pediatric Surgery0 个研究点目标入组 23 人开始时间: 2014年11月17日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1).Prior radiotherapy or chemotherapy (2).Grade 2 or greater peripheral neuropathy (3).Blood transfusion, administration of blood products, or hematopoietic (e.g., G-CSF) support within 7 days before enrollment (4).Having UGT1A1*6/*6, UGT1A1*28/*28, or UGT1A1*6/*28 gene (5).Moderate ascites (6).Intestinal pneumonitis or pulmonary fibrosis (7).Watery stool within 3 days before enrollment (8).Clinically significant heart disease (9).Active infection (HBS,HCV) (10).Uncontrolled diabetes mellitus (11).Serious complications (organ failure, or uncontrolled diabetes mellitus) (12).Serious complications (mental disorder, or central nervous system disorders) (13).Serious drug allergy (14).Active double cancer (15).Pregnancy (16).Treatment with atazanavir sulfate (17).Inappropriate for this study judged by the attending physician

发起方

Tokyo Medical University Department of Gastrointestinal and Pediatric Surgery